SSKN Strata Skin Sciences

STRATA Skin Sciences Reschedules Fourth Quarter 2022 Conference Call and Webcast to Friday, March 31, 2023

STRATA Skin Sciences Reschedules Fourth Quarter 2022 Conference Call and Webcast to Friday, March 31, 2023

HORSHAM, Pa., March 28, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced it will release its fourth quarter 2022 financial results along with its Form 10-K on Friday, March 31, 2023. Management will hold a conference call to review the financial results and provide a corporate update starting at 8:30 AM EDT on the same day.

Friday, March 31, 2023, 8:30 AM EDT

Domestic: 877-269-7756

International: 201-689-7817

Conference ID: 13736453

Webcast:

After the live webcast, the event will be archived for future reference on the STRATA Skin Sciences website at under the investor relations section.

About STRATA Skin Sciences, Inc.

STRATA Skin Sciences is a medical technology company dedicated to developing, commercializing and marketing innovative products for the in-office treatment of various dermatologic conditions such as psoriasis, vitiligo, and acne. Its products include the XTRAC® and Pharos® excimer lasers, VTRAC® lamp systems, and now the TheraClear®X Acne Therapy System.

STRATA is proud to offer these exciting technologies in the U.S. through its unique Partnership Program. STRATA’s popular partnership approach includes a fee per treatment cost structure versus an equipment purchase, installation and use of the device, on-site training for practice personnel, service and maintenance of the equipment, dedicated account and customer service associates, and co-op advertising support to help raise awareness and promote the program within the practice.

Investor Contact:

Rich Cockrell

CG Capital

Phone: +1 (404) 736-3838

tal



EN
28/03/2023

Underlying

SSKNStrata Skin Sciences

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Strata Skin Sciences

 PRESS RELEASE
Free
SSKN Strata Skin Sci...

STRATA Skin Sciences Confirms Nasdaq Delisting

STRATA Skin Sciences Confirms Nasdaq Delisting HORSHAM, Pa., Feb. 19, 2026 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that a Form 25 has been filed today with the SEC to deregister its common stock under Section 12(b) of the Securities Exchange Act of 1934, as amended (“Exchange Act”), and confirms that trading of the Company’s common stock has been suspended from trading on The Nasd...

February 19, 2026 1 EN
 PRESS RELEASE
Free
SSKN Strata Skin Sci...

Johns Hopkins Dermatology Expands Advanced Care for Inflammatory and A...

Johns Hopkins Dermatology Expands Advanced Care for Inflammatory and Autoimmune Skin Conditions with Addition of XTRAC® Excimer Laser Latest STRATA customer strengthens academic leadership in XTRAC excimer laser treatment for psoriasis, vitiligo, and atopic dermatitis HORSHAM, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (Nasdaq: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative dermatologic treatments, today announces that Johns Hopkins Dermatology has added the XTRAC® 308 nm excimer laser to its clinical treatme...

February 18, 2026 1 EN
 PRESS RELEASE
Free
SSKN Strata Skin Sci...

STRATA Skin Sciences Highlights Meta-Analysis Confirming Clinical Effi...

STRATA Skin Sciences Highlights Meta-Analysis Confirming Clinical Efficacy of 308 nm Excimer Laser for Plaque Psoriasis Growing body of clinical data like February 2026 publication from Georgetown University supports optimized, targeted Excimer laser UVB strategies for inflammatory skin conditions HORSHAM, Pa., Feb. 17, 2026 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative dermatologic treatments, today highlights findings from a February 2026 systematic review and meta-analysis...

February 17, 2026 1 EN
 PRESS RELEASE
Free
SSKN Strata Skin Sci...

STRATA Skin Sciences Showcases XTRAC® and TheraclearX® at TeraCILAD 20...

STRATA Skin Sciences Showcases XTRAC® and TheraclearX® at TeraCILAD 2025 — Reports Early Adoption Momentum in Mexico HORSHAM, Pa., Dec. 09, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a global leader in in-office dermatologic technologies, announces its participation in the 2025 Ibero-Latin American Congress of Dermatology (TeraCILAD) November 19-22, 2025, where it presented its XTRAC® excimer laser and TheraclearX® acne therapy system. STRATA also reported that, by the end of 2025, there will be over 12 new recurring TheraclearX® accounts in Mexico, reflecting gro...

December 9, 2025 1 EN
Free Trial
SSKN Strata Skin Sci...

Strata Skin Sciences Inc: 1 director

A director at Strata Skin Sciences Inc sold/bought 19,094 shares at 1.334USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last tw...

SSKN STRATA SKIN SCIENCES
11/19/25 November 19, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch